PHARMACY

Diplomat clinical services manager gets oncology pharmacist certification

BY David Salazar
FLINT, Mich. — Diplomat Pharmacy announced this week that Kelly Procailo, the company’s clinical oncology manager inside its Clinical Services department has received certification as a Board Certified Oncology Pharmacist (BCOP) from the Board of Pharmacy Specialties. 
 
Procailo joins some 1,900 oncology pharmacists in the United States. At Diplomat, she oversees therapeutic and medication protocols and decision tools, drives policy and procedural development and provides clinical support for all oncology initiatives. She also serves on the University of Michigan’s College of Pharmacy board of governors and is a member of the Hematology and Oncology Pharmacists Association and the American Society of Clinical Oncology. 
 
“We are proud of Dr. Procailo's accomplishment," Diplomat SVP clinical services and human resources Gary Rice said. “She brings additional knowledge and experience to the Diplomat oncology team that will ultimately improve patient care initiatives and programs.”
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Health Canada allows immediate access to Narcan nasal spray

BY David Salazar
OTTAWA — Canada’s minister of health on Wednesday signed an interim order that will bring immediate access to Narcan (naloxone) nasal spray. The order allows the nasal spray, made by Adapt Pharma, to be imported from the U.S. and sold in Canda, where only the injectable version of the opioid overdose reversal drug had been available. 
 
Health Canada is currently reviewing an application for the nasal spray’s authorization to be sold in the country, but health minister Jane Philpott said the interim order will ensure access during the review period and potentially save lives. 
 
“The number of opioid overdoses in Canada is nothing short of a public health crisis,” Philpott said. “First responders, police and family members need immediate access to formats of naloxone that are easy to use so that needless deaths can be prevented. Extraordinary measures are required to address this crisis, so I have asked my department to conduct an expedited review of nasal naloxone for sale in Canada, and to enact this temporary measure that allows access to a product from the US while our review is underway.”
 
The nasal spray will be provided alongside English and French instructions for use. Besides making Narcan nasal spray available, Canada’s government has been educating citizens about safe use, storage and disposal of prescription drugs while increasing inspections to keep drugs from being diverted from pharmacies and improving surveillance data on prescription drug abuse. The government has also been working with First Nations communities to enhance prevention and treatment of opioid-related issues. 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Taro CEO to step down, head to Sun Pharma HQ

BY David Salazar
HAWTHORNE, N.Y. — Taro Pharmaceuticals on Thursday announced that its CEO Kal Sundaram would be stepping down as CEO at the end of 2016. Sundaram will be returning to India, where he will assume an executive position at Sun Pharma’s global headquarters (Taro is a U.S. subsidiary of Sun Pharma). 
 
“On behalf of Taro’s entire Board, I want to thank Kal for his many contributions to Taro — providing significant leadership over a challenging period for both the company and the industry, his commitment and dedication to being a driving force behind Taro’s strategic direction, and leading the company on a steady and consistent growth path – delivering strong financial and operational performance,” Taro chairman Dilip Shanghvi said. 
 
Taro’s board will conduct a formal process to appoint a CEO to solely focus on Taro, which Sundaram will assist with. He will stay on board until the end of 2016. 
 
“I am grateful and privileged to be associated with Taro for the past four years as a Board member and three years as CEO. I am also proud of what the Taro team has accomplished during that time,” Sundaram said. “By all measures, the company has executed very well over the past several years, and as a result, Taro is well positioned for continued growth and success. I’d like to thank the Board, the executive management team, and Taro’s employees for their support throughout the years.”
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?